The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique.
INTRODUCTION
transmembrane ionic channels, has been successfully used in patients to control cardiac arrhythmias [12, 14] . Amiodarone, although lengthens ventricular repolarization and blocks inward sodium channels, has relatively low proarrhythmic activity [14] , suggesting that combination of these two effects is not necessarily harmful. Amiodarone, however, has several and some serious extracardiac side effects, likely associated to its specific chemical structure. This limits the long-term use of the drug in many patients. Therefore, great effort is being made world-wide to developed new amiodarone-like antiarrhythmic drugs free from serious side effects. In the Drug Research Institute, in the course of an intensive chemical synthetic program, new compounds were synthetized, which electrophysiologically resembled amiodarone in the sense that they had combined Class IB and Class III antiarrhythmic properties without structural relationship with amiodarone. In this study we describe the effect of one of this compounds, GYKI 16638 ( Fig. 1) , on the action potentials in undiseased human ventricular muscle in comparison with sotalol and mexiletine.
Many new antiarrhythmic drugs have been introduced into the therapy but the pharmacological treatment of ventricular arrhythmias is not always successful and it is often associated with life-treathening proarrhythmic complications. One type of proarrhythmia relates to the impairment of impulse conduction due to the block of the fast inward sodium channels and was attributed to the increased mortality after oral flecainide and encainide treatment reported in the CAST trial [6] . The other type of proarrhythmia was noticed with drugs like sotalol, which lengthens repolarization in a reverse rate-dependent manner and can induce early afterdepolarization (EAD) [25] leading, in certain patients, to torsade de pointes chaotic ventricular tachycardia [16] . This latter was postulated to explain the increased mortality after d-sotalol treatment in the SWORD [28] trial. However, amiodarone, a drug with multiple modes of action [12] After measuring the action potential parameters (maximal sampling rate = 50 kHz) at the basic cycle length of 1000 ms, 9 different constant stimulation cycle lengths (300, 400, 500, 700, 1000, 1500, 2000, 3000 and 5000 ms) were applied. Action potential parameters were measured at each cycle length following "quasi steady state" adaptation (25 beats) to the new pacing cycle length. To determine the recovery (offset) kinetics of V max , extra stimuli (S2) were applied with gradually increasing coupling interval from the basic cycle length (S1-S1) of 1000 ms after every 20th basic stimulus (S1). Diastolic interval was determined as a time interval corresponding to the difference between the timing of the extra stimulus (S1-S2) and the time point of the APD 90 of the preceding basic action potential.
donor hearts used for homograph valve transplantation surgery. The experimental protocol complied with the Declaration of World Medical Association proclaimed in Helsinki and was approved by the Ethical Review Board of the Albert Szent-Györgyi Medical University (No. 51-57/1997 OEj). 16 preparations were used from 16 patients (mean age 40.0 ± 0.3, years, 8 females and 8 males). The patients did not receive medication other than dobutamine, furosemide or plasma volume expanders. Before preparation, the hearts were perfused with cardioplegic solution and were kept cool (4-6°C) for 2-4 hours. Than the trabecular and papillary muscles were excised and mounted in a tissue chamber (volume ≈ 50 ml) in oxygenated (95% O 2 + 5% CO 2 ) modified Tyrode's solution containing (in mM): NaCl, 115; KCl, 4; CaCl 2 , 1.8; MgCl, 1; NaHCO 3 , 20; and glucose, 11 at 37 °C. The pH of this solution was 7.35 to 7.45.
After control measurements drugs were superfused for 40-60 minutes and measurements were repeated. When impalements were lost, reimpalements were attempted. If the new impalement deviated more than 5 % from the preceding one, the experiment was excluded from the evaluation. Dsotalol (Bristol-Myers Co. Wallingford, CT, USA) and Mexiletine (IDR Ltd. Budapest, Hungary) were prepared daily from aqueous stock solutions (30 mM and 10 mM) to obtain the final drug concentration in the tissue bath. GYKI 16638 (IDR Ltd. Budapest, Hungary) was diluted similarly but from 10 mM stock solution containing 50 % DMSO. At concentrations less than 0.2 % DMSO did not affect action potential parameters established in separate measurements.
Each preparation was initially stimulated at a basic cycle length of 1000 ms (frequency = 1 Hz), using 2 ms long rectangular constant voltage pulses isolated from ground and delivered via bipolar platinum electrodes in contact with the preparation by a EMG 4747 type stimulator. At least 1 hour was allowed for each preparation to equilibrate while they were continuously superfused with the Tyrode's solution. Transmembrane potentials were recorded using the conventional microelectrode recording technique. Microelectrodes filled with 3 M KCl and having tip resistances 5-20 MΩ were connected to the input of a high impedance electrometer (Biologic VF102), which was referenced to the ground. The first derivative of the transmembrane potentials (V max ) was electronically derived by a Biologic DV-140 Differentiator. The voltage outputs from all amplifiers were connected after digitalisation (ADA 3300 AD board) to an IBM 386-486 microprocessor base personal computer for data acquisition and also displayed on Student 's t test for paired data was used to compare the results statistically. Results were considered significant when P was found to be less than 0.05.
RESULTS
The effect of 5 µM GYKI 16638 on the basic action potential parameters was studied at 1 Hz stimulation for repolarization in the whole range of the studied cycle lengths (400-5000 ms).
The frequency dependent effect of GYKI 16638, sotalol and mexiletine on the V max was also studied. Sotalol (30 µM), as expected from previous animal studies [21, 22] , did not change significantly V max at any stimulation cycle lengths (Fig. 3B) , while both 10 µM mexiletine and 5 µM GYKI 16638 exerted rate dependent V max depression i.e. the higher stimulation rate was associated with more V max block (Fig. 3B) . The characteristics of this frequency dependent V max block was very similar with mexiletine and GYKI 16638 i.e. both drugs depressed V max only at cycle lengths shorter than 1000 ms. This rate-dependent V max block was the consequence of the slowing of the recovery of sodium channels from inactivation, which was studied by applying second stimuli with increasing coupling intervals during the diastole from a basic cycle length of 1000 ms. In control condition i.e. before drug administration and also after sotalol superfusion, V max value returned, within 30-40 ms during early diastole, almost to its value characteristic at the basic cycle length. In marked contrast, after mexiletine and GYKI 16638 administration the recovery of V max was considerably delayed and could be characterised with
The frequency dependent effect of GYKI 16638, sotalol and mexiletine was investigated on the APD 90 and V max in the range of stimulation cycle length between 300 and 5000 ms. Results are shown in Fig. (3A) . Sotalol (30 µM) increased APD considerably more at long cycle lengths than at short ones, i.e. it induced strong reverse rate-dependent APD prolongation. In contrast, mexiletine (10 µM) shortened APD. This APD shortening was minimal and statistically not significant at high stimulation frequencies i.e. at short cycle lengths, while it proved to be significant at longer cycle lengths. The magnitude of the APD lengthening effect of GYKI 16638 (5 µM) was marked but less than that of sotalol. This APD prolongation, however, unlike that induced by sotalol, was apparently independent of the rate of stimulation i.e. the drug elicited similar increase of the time The effect of GYKI 16638 on the action potential and transmembrane ionic currents is currently under investigation. Preliminary results showed that it lengthened APD and blocked V max in rabbit cardiac papillary muscle [2] and depressed the rapidly activating delayed rectifier potassium (I Kr ) and inward rectifier potassium (I k1 ) currents in rabbit ventricular myocytes [2] . In addition, in dog, rabbit and rats the compound exerted in vivo antiarrhythmic effect comparable to that of sotalol [2] .
DISCUSSION
The purpose of the present experiments was to examine the cellular electrophysiological effects of GYKI 16638, in comparison with sotalol and mexiletine, in isolated undiseased human ventricular muscle. The most important result of this study is that GYKI 16638, unlike sotalol, lengthened repolarization in a frequency independent manner, while like mexiletine, it decreased V max only at heart rates faster than the normal range.
The purpose of the chemical synthesis of the GYKI compounds was to develop an antiarrhythmic drug, which would be devoid of the proarrhythmic potential of the selective Class III and Class I drugs, and does not exhibit serious extracardiac side effects. To achieve this latter goal, the chemical structure of GYKI does not resemble that of amiodarone, but shows similarities with the structure of both sotalol and mexiletine (Fig. 1) . Combining Class IB and Class III antiarrhythmic effects was reported to attenuate reverse rate-dependent prolongation of APD [25] and abolished EAD formation [25] commonly seen after administration of pure Class III drugs. It was also reported that erythromycine induced torsade de pointes arrhythmia was successfully abolished with mexiletine in a patient [10] . Although some clinical reports [27] suggested strong antiarrhythmic effect of the combination of Class IB and Class III drugs, no large scale clinical trial has been initiated to establish the real therapeutic value of such combination.
The two drugs, sotalol and mexiletine, which were used for comparison, were investigated previously intensively on the ventricular action potential in different mammalian preparations, including in some experiments ventricular trabecular muscle obtained from explanted endstage heart failure human heart [13] , but the effects of these drugs on the action potential characteristics have never been established directly in undiseased human ventricular muscle. Sotalol, which has been classified as Class III antiarrhythmic drug [21] has been reported to lengthen APD in a reverse ratedependent manner without affecting V max [22] . In this study we confirmed these earlier observations made in animal preparations and in vivo clinical electrophysiological measurements [11] . Mexiletine, a drug which has been classified as a Class IB antiarrhythmic [4] , according to earlier investigations performed also in animal preparations (5, 8, 24, 25) and in vivo clinical electrophysiological measurements [9] , shortened or did not change APD Amiodarone, however, is a drug, which has strong antiarrhythmic efficacy in patients, while showing promising results regarding mortality in multicenter clinical trials [7] . In addition, amiodarone treatment is associated with low incidence of proarrhythmic complication [14] . Amiodarone, besides other effects, possesses strong rate-independent Class III [18] and Class IB [18, 23] properties. These favourable effects of amiodarone can be, at least partly, attributed to its peculiar cellular electrophysiologic properties. Amiodarone induced strong rate dependent V max block [15, 23] with fast offset kinetics [18, 23] . Also, chronic amiodarone treatment lengthened repolarization rate-independently (18) and decreased I Kr density in rabbit ventricular muscle [26] . It is important to note that both acute [18] and chronic [20] amiodarone administration abolished EAD formation in dog Purkinje fibers [18] and M cells [20] alike. This latter effect can be attributed to the depression of the slowly inactivating [3] or window [1] sodium current, which would limit the undesirable consequence of I Kr block, resulting in rateindependent APD prolongation and minimal increase of dispersion of repolarization. Based on its cellular electrophysiological effects, a similar mechanism can be postulated with GYKI 16638. The present has, however, some possible limitations. We have applied only one drug concentration. Taking into consideration the diffusion barrier and the time course of the experiments, the selected drug concentrations were somewhat higher, but still close to the therapeutic plasma concentrations measured in patients with sotalol [11, 16, 29] and mexiletine [9, 17] and established with GYKI 16638 (1-2 µM) in pharmacokinetic investigations. Also, we applied only right ventricular endocardial preparations, which may not well represent the whole heart [19] . These limitations are explained by the difficulty in obtaining human ventricular preparations for experimental purpose.
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[ In conclusion, in human ventricular muscle GYKI 16638 shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiologic manifestation seen after chronic amiodarone treatment. GYKI 16638 can therefore be a useful new antiarrhythmic drug candidate for further studies in animal experiments and also in patients.
